Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, raised $224 million by offering 14 million shares at the $16, in line with the upwardly revised terms. The company originally planned to offer 10 million shares at $14 to $16 before increasing its proposed deal size on Thursday. At pricing, the company commands a fully diluted market cap of $1.0 billion.
Poseida Therapeutics plans to list on the Nasdaq under the symbol PSTX. BofA Securities, Piper Sandler and William Blair acted as lead managers on the deal.
